Skip to main content

Table 1 Baseline characteristics

From: Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial

Characteristic Sildenafil group (n = 20) Placebo group (n = 20) Total (n = 40)
Age (years) (median, IQR) 59 (41–69) 57 (45–67) 57 (41–68)
Male sex (n, %) 16 (80%) 17 (85%) 33 (82.5%)
Symptom duration (days) (median, IQR) 9 (7–11) 8 (6.5–10) 8 (7–10)
Active smoker (n, %) 3 (15%) 2 (10%) 5 (12.5%)
Asthma (n, %) 1 (5.0%) 1 (5.0%) 2 (5.0%)
Chronic obstructive pulmonary disease (n, %) 0 (0%) 0 (0%) 0 (0%)
Arterial hypertension (n, %) 10 (50%) 10 (50%) 20 (50%)
Diabetes mellitus (n, %) 4 (20%) 4 (20%) 8 (20%)
Charlson comorbidity index score (median, IQR) 1 (0–3) 1 (0–3) 1 (0–3)
Ambient oxygen (n, %) 6 (30%) 7 (35%) 13 (32.5%)
Awake prone positioning (n, %) 5 (25%) 6 (30%) 11 (27.5%)
High-flow nasal cannula (n, %) 1 (5%) 1 (5%) 2 (5%)
Oxygen support flow (Lts/min, median, IQR) 1 (0–4.5) 2.5 (0–5) 2 (0–5)
Laboratory    
Arterial pH (median, IQR) 7.45 (7.43–7.48) 7.45 (7.43–7.47) 7.45 (7.44–7.47)
Arterial oxygen partial pressure (PO2, mmHg) (median, IQR) 83.3 (70.7–87.5) 84.1 (76.5–95.0) 83.3 (75.4–90.1)
Arterial carbon dioxide partial pressure (mmHg) (median, IQR) 33 (31.2–34.7) 36.2 (31.3–37.7) 33.4 (31.2–36.9)
Bicarbonate (mEq/Lt) (median, IQR) 23.7 (21.3–25.1) 24.2 (22.6–26.9) 24.0 (22.4–25.6)
PaO2/FiO2 ratio (median, IQR) 308 (216–366) 299 (220–359) 302 (216–365)
A-a gradients (median, IQR) 51.6 (40.3–133) 71.0 (37.3–149) 66 (40–146)
D-Dimer (ng/mL) (median, IQR) 271 (191–404) 287 (170–545) 284 (190–424)
Absolute lymphocyte count (cells/mm3) (median, IQR) 860 (730–1200) 860 (680–1120) 860 (680–1160)
Lactate dehydrogenase (UI/L) (median, IQR) 320 (252–355) 310 (271–488) 316 (254–398)
C-Reactive protein (mg/L) (median, IQR) 90.3 (35.6–187.0) 98.0 (63.3–139.0) 92.5 (56.6–179)
Serum creatinine (mg/dL) (median, IQR) 0.87 (0.79–1.0) 0.78 (0.73–0.87) 0.82 (0.75–0.93)
Serum blood urea nitrogen (mg/dL) (median, IQR) 18.2 (14.9–20.6) 15.2 (11.0–18.1) 16.7 (12.5–19.6)
Computed tomography    
Pulmonary embolism (n, %) 0 (0%) 1 (5.0%) 1 (2.5%)
Vascular beaded appearance (n, %) 11 (55%) 10 (50%) 21 (52.5%)
CT severity score (median, IQR) 9 (7–10) 9 (7.5–10) 9 (7–10)
sCTA perfusion score (median, IQR) 10 (8–10) 10 (8–10) 10 (8–10)